Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?

Anwin Joseph Kavanal; Santosh Ranjan Jena; Rajender Kumar; Chandan Krushna Das; Sunil Kumar; Bhagwant Rai Mittal

doi:10.2967/jnmt.121.262145

Effect of COVID-19 on ¹⁸F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning ¹⁸F-FDG PET/CT for Oncologic Evaluation?

J Nucl Med Technol. 2021 Sep;49(3):284-285. doi: 10.2967/jnmt.121.262145. Epub 2021 Jul 9.

Authors

Anwin Joseph Kavanal¹, Santosh Ranjan Jena¹, Rajender Kumar¹, Chandan Krushna Das², Sunil Kumar¹, Bhagwant Rai Mittal³

Affiliations

¹ Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and.
² Medical Oncology OPD, Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
³ Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and brmittal@yahoo.com.

Abstract

Incidental detection of coronavirus disease 2019 (COVID-19)-related lung changes on ¹⁸F-FDG PET/CT images of oncology patients has been increasingly reported. Most of the case reports or series have stressed the retrospective diagnosis of COVID-19 with the help of ¹⁸F-FDG PET/CT lung findings. In this case report, we introduce a different aspect of COVID-19-related lung changes on ¹⁸F-FDG PET/CT, interfering with the evaluation of metastatic lung lesions in a patient with renal cell carcinoma.

Keywords: 18F-FDG PET/CT; COVID-19; lung metastasis; renal cell carcinoma; response evaluation.

Publication types

Case Reports

MeSH terms

COVID-19*
Fluorodeoxyglucose F18*
Humans
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
Retrospective Studies
SARS-CoV-2

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18